Marea Therapeutics
Small molecule therapeutics targeting cardiometabolic diseases using human genetic insights
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2021
- Latest Form D
- $65.4M, Jun 2024
- Total capital
- $65.4M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $65.4M
- 1 Form D · last Jun 2024
- 28 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$65.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Aaron RoystonDirectorNamed in SEC Form D filings
- Antoine BoulangerDirectorNamed in SEC Form D filings
- Caitlin MurrayExecutive OfficerNamed in SEC Form D filings
- Chris GarabedianDirectorNamed in SEC Form D filings
- Christine GarrettExecutive OfficerNamed in SEC Form D filings
- Ethan WeissExecutive OfficerNamed in SEC Form D filings
Show all 12 people
- Jeff TongDirectorNamed in SEC Form D filings
- Josh LehrerExecutive Officer, DirectorNamed in SEC Form D filings
- Jung ChoiDirectorNamed in SEC Form D filings
- Maha KatabiDirectorNamed in SEC Form D filings
- Mark JoingExecutive OfficerNamed in SEC Form D filings
- Ted LoveDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingAngiopoietin-like Protein 4 Antibody-based TreatmentUSPTOApplication 63801047
- PendingAngiopoietin-like Protein 4 Antibody-based TreatmentUSPTOApplication 63775940
- PendingAngiopoietin-like Protein 4 Antibody-based TreatmentUSPTOApplication 63768015
Show all 5 patent records
- Angiopoietin-like Protein 4 Antibody-based TreatmentApplication 63801047Pending
- Angiopoietin-like Protein 4 Antibody-based TreatmentApplication 63775940Pending
- Angiopoietin-like Protein 4 Antibody-based TreatmentApplication 63768015Pending
- Angiopoietin-like Protein 4 Antibody-based TreatmentApplication 63744715Pending
- Angiopoietin-like Protein 4 Antibody-based TreatmentApplication 63661011Pending
Related companies, and why
- AbbraTech Holdings LLCSimilar federal contract value in Biotech · null in contracts
- Phycin, Inc.Similar federal contract value in Biotech · null in contracts
- SymbioCellTech, LLCSimilar federal contract value in Biotech · null in contracts
- Belenos Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Brenig TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Cadenza Bio, Inc.Similar federal contract value in Biotech · null in contracts
Press
After one failed acquisition attempt, Lisata finds lifeline in Marea mergerFierceBiotech
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .